Regaining compliance with Nasdaq's requirements is a significant positive development for Elutia Pharmaceuticals. It removes the immediate risk of delisting, which can be detrimental to a company's stock price and investor perception. This news is likely to be viewed positively by investors and could lead to a short-term increase in the stock price as it alleviates concerns over the company's ability to meet exchange standards.